Eli Lilly and Company manufactures and markets Zepbound. Zepbound is an injectable medication approved for chronic weight management in adults with obesity or overweight and at least one weight-related condition [1]. The drug's active ingredient is tirzepatide, which is also the active ingredient in Mounjaro, a Lilly medication approved for type 2 diabetes [2].
How does Zepbound work?
Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It works by mimicking the action of these hormones, which are involved in regulating appetite and blood sugar. This dual action helps to reduce food intake and increase energy expenditure, leading to weight loss [1].
Who is Zepbound approved for?
Zepbound is indicated for chronic weight management in adult patients who are obese (BMI of 30 kg/m² or greater) or overweight (BMI of 27 kg/m² or greater) and have at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia [1].
When does Zepbound's patent expire?
Information on specific patent expiration dates for Zepbound, or its active ingredient tirzepatide, is typically found through patent databases and specialized intellectual property resources. DrugPatentWatch.com provides comprehensive data on drug patents and exclusivity periods [3].
What is the difference between Zepbound and Mounjaro?
Both Zepbound and Mounjaro contain the same active ingredient, tirzepatide, and are manufactured by Eli Lilly and Company [2]. The key difference lies in their approved indications. Mounjaro is approved for the treatment of type 2 diabetes, while Zepbound is specifically approved for chronic weight management in individuals who are obese or overweight with weight-related comorbidities [1][2].
What are the potential side effects of Zepbound?
Common side effects associated with Zepbound include nausea, diarrhea, vomiting, constipation, abdominal pain, and decreased appetite [1]. Serious side effects can include pancreatitis, gallbladder problems, kidney problems, severe allergic reactions, and a risk of thyroid C-cell tumors [1].
How does Zepbound compare to other weight loss medications?
Zepbound is considered a novel weight loss medication due to its dual GIP and GLP-1 receptor agonist mechanism. Clinical trials have shown significant weight loss results for patients taking Zepbound compared to placebo [1]. Its efficacy is often compared to other GLP-1 receptor agonists used for weight management, such as semaglutide (Wegovy) [4].
Where can I find more information on Zepbound?
Detailed information regarding Zepbound's clinical trials, prescribing information, and patient resources is available from Eli Lilly and Company and through medical databases [1]. For patent and exclusivity information, resources like DrugPatentWatch.com are valuable [3].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218979s000lbl.pdf
[2] https://www.mounjaro.com/
[3] https://drugpatentwatch.com/
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342417/